Safety and efficacy of lenalidomide (Revlimid®) in recurrent ovarian and primary peritoneal carcinoma

Gynecologic Oncology

Volumn 105, Issue 1, 2007, Pages 194-198

  Zhang, Mallory M ^a   Chan, John K ^a   Husain, Amreen ^a   Guo, Hong Yan ^a   Teng, Nelson N H ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Immunomodulatory drug; Lenalidomide; Ovarian cancer; Revlimid

Indexed keywords

ANTICOAGULANT AGENT; CA 125 ANTIGEN; CYTOTOXIC AGENT; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOMODULATING AGENT; LENALIDOMIDE; PLATINUM;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ARTICLE; BACKACHE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DECREASED APPETITE; DEEP VEIN THROMBOSIS; DIAGNOSTIC IMAGING; DIARRHEA; DISEASE COURSE; DIZZINESS; DRUG ACTIVITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRY SKIN; DYSPNEA; FAILURE TO THRIVE; FATIGUE; FEMALE; GASTROESOPHAGEAL REFLUX; HEART ARRHYTHMIA; HUMAN; HUMAN TISSUE; IMMUNOMODULATION; LABORATORY TEST; LEG EDEMA; MEMORY DISORDER; MULTIPLE CYCLE TREATMENT; MUSCLE CRAMP; NAIL DISEASE; NAUSEA; NEUTROPENIA; OVARY CARCINOMA; PERIPHERAL NEUROPATHY; PERITONEUM CANCER; PHASE 1 CLINICAL TRIAL; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; TASTE DISORDER; THROMBOEMBOLISM; TINNITUS; TREATMENT DURATION; TREATMENT RESPONSE; VISUAL DISORDER; XEROSTOMIA;

ADULT; AGED; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; THALIDOMIDE;

EID: 33947317268     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2006.11.026     Document Type: Article

References (22)

1. Latorre A., De Lena M., Catino A., et al. Epithelial ovarian cancer: second and third line chemotherapy. [review]. Int. J. Oncol. 21 (2002) 179-186
2. Bartlett J.B., Dredge K., and Dalgleish A.G. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat. Rev., Cancer 4 (2004) 314-322
3. Teo S.K., Stirling D.I., and Zeldis J.B. Thalidomide as a novel therapeutic agent: new uses for an old product. Drug Discovery Today 10 (2005) 107-114
4. Eisen T., Boshoff C., Mak I., et al. Continuous low dose thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br. J. Cancer 82 (2000) 812-817
5. Abramson N., Stokes P.K., Luke M., Marks A.R., and Harris J.M. Ovarian and papillary-serous peritoneal carcinoma: pilot study with thalidomide. J. Clin. Oncol. 20 (2002) 1147-1149
6. Richardson P.G., Schlossman R.L., Weller E., et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 100 (2002) 3063-3067
7. Lee C.P., Patel P.M., Selby P.J., et al. Randomized phase II study comparing thalidomide with medroxyprogesterone acetate in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 24 (2006) 898-903
8. Corral L.G., Haslett P.A., Muller G.W., et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J. Immunol. 163 (1999) 380-386
9. Bartlett J.B., Michael A., Clarke I.A., et al. Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers. Br. J. Cancer 90 (2004) 955-961
10. Common Terminology Criteria for Adverse Events, Version 3.0: National Cancer Institute.
11. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 92 (2000) 205-216
12. Basen-Engquist K., Bodurka-Bevers D., Fitzgerald M.A., et al. Reliability and validity of the functional assessment of cancer therapy-ovarian. J. Clin. Oncol. 19 (2001) 1809-1817
13. Tohnya T.M., Ng S.S., Dahut W.L., et al. A phase I study of oral CC-5013 (lenalidomide, Revlimid), a thalidomide derivative, in patients with refractory metastatic cancer. Clin. Prostate Cancer 2 (2004) 241-243
14. Teo S.K. Properties of thalidomide and its analogues: implications for anticancer therapy. Aaps J. 7 (2005) E14-E19
15. Dredge K., Horsfall R., Robinson S.P., et al. Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. Microvasc. Res. 69 (2005) 56-63
16. Marriott J.B., Clarke I.A., Dredge K., Muller G., Stirling D., and Dalgleish A.G. Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells. Clin. Exp. Immunol. 130 (2002) 75-84
17. Zhang L., Conejo-Garcia J.R., Katsaros D., et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348 (2003) 203-213
18. Margolin K., Gordon M.S., Holmgren E., et al. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J. Clin. Oncol. 19 (2001) 851-856
19. Gordon M.S., Margolin K., Talpaz M., et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J. Clin. Oncol. 19 (2001) 843-850
20. Scarpace S.L., Hahn T., Roy H., et al. Arterial thrombosis in four patients treated with thalidomide. Leuk. Lymphoma 46 (2005) 239-242
21. Zangari M., Anaissie E., Barlogie B., et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 98 (2001) 1614-1615
22. G.C. MR Manuel, J.K. Chan, A. Husain, N.N.H. Teng, Safety and efficacy of thalidomide in recurrent epithelial ovarian and primary peritoneal carcinoma. Presented at the 29th Annual Meeting of the Western Association of Gynecologic Oncologists.